Respiratory syncytial virus

Nirsevimab FAQs

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

Kuwait taking the lead in RSV protection for all infants in the Middle east

Podcast Dr. Dana Hajan

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

An easy guide to use Nirsevimab